AB 12
Alternative Names: AB 12 IV; AB 12 PO; AB-12Latest Information Update: 26 Aug 2024
At a glance
- Originator AUTOTAC Bio
- Class Antidementias
- Mechanism of Action Apoptosis stimulants; Tau protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease
Most Recent Events
- 02 Aug 2024 Preclinical trials in Alzheimer's disease in South Korea (PO) (AUTOTAC Bio pipeline, August 2024)
- 02 Aug 2024 Preclinical trials in Alzheimer's disease in South Korea (IV) (AUTOTAC Bio pipeline, August 2024)
- 02 Aug 2024 AUTOTAC Bio plans a phase I trial for Alzheimer's disease in between 2024 to 2025 (PO) (AUTOTAC Bio pipeline, August 2024)